Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Targeting Vps34 makes melanoma and CRC eligible to anti–PD-1/PD-L1 blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In a mouse CRC model, the autophagy inhibitors, such as SB02024 and SAR405, increased NK and T cell infiltration in TME and reversed resistance to anti-PD-1 or anti-PD-L1 [47].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [47]
The cited source says what the claim attributes to it.
In the citing paper
“Supporting this finding, lysosomotropic agents or small molecules targeting the PtdIns3K PIK3C3/VSP34 have been efficiently combined with therapeutic regimens that promote the activation of the immune system against cancer cells (Janji et al, 2020; Noman et al, 2020).”
From Autophagy in major human diseases (2021) · cites this paper as Noman et al, 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 2×
“This statement is supported by clinical data showing that the presence of preexisting T cells close to the invasive tumor margin is a key determinant to achieving a long-lasting response to anti–PD-1 therapy in melanoma (4).”
Autophagy: Renovation of Cells and Tissues
Mizushima, N., & Komatsu, M. (2011) · Cell · doi:10.1016/j.cell.2011.10.026 · Cited by 6,418
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · cited 5×
“INTRODUCTION Immune checkpoint inhibitors (ICIs), exemplified by antibodies targeting programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1), are groundbreaking treatment for many cancers, including melanoma (1).”
InfluentialChemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206 · cited 1×
“CCL5, CXCL10, and IFN are all known to promote recruitment of cytotoxic T cells into the TME (18), and this is likely the explanation for why we observed enhanced recruitment of NK, CD8+ T, and CD4+ T effector cells into the tumor bed following Vps34 inhibition.”
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Self-citationCurran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874 · cited 1×
“We used melanoma B16F10, previously described as immune hot tumors but not responding to anti–PD-L1/PD-1 (21), and CRC CT26, reported as immune cold tumors and partially responding to anti–PD-L1/PD-1 (22).”
Pancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498 · cited 1×
“While the impact of blocking autophagy on the inhibition of tumor growth has been well documented by several studies ( 7 , 8 , 14 , 23 – 26 ), the effect of targeting autophagy on the immune landscape of tumors is still only partially defined.”
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · cited 1×
“In this regard, it is tempting to speculate that type I IFN signature could be responsible for triggering the release of more CCL5 and CXCL10 in the TME, as previously reported (37), to attract more NK and CD8+ T cells into the tumor bed.”
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000 · cited 1×
“The immune phenotyping of tumors combined with the cytokine network results reported in this study strongly predicts that the immune-supportive characteristic of Vps34itreated TME relies on the establishment of an inflamed TME supported by the presence of tumor-infiltrating lymphocytes, high levels of IFN-producing C…”
Cited by
Items 201–268 of 268
Malla, R. R., Pappu, L., Amajala, K. C., & Kamal, M. A. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220324143215 · Cited by 2
Ji, S., Li, J., Duan, X., Zhang, J., Zhang, Y., Song, M., Li, S., Chen, H., & Ding, D. (2021) · Angewandte Chemie · doi:10.1002/ange.202110512 · Cited by 2
Lamsal, A., Andersen, S. B., Johansson, I., Desgarnier, M. D., Wolowczyk, C., Engedal, N., Vietri, M., Bjørkøy, G., Giambelluca, M. S., & Pettersen, K. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01858-6 · Cited by 2
“Moreover, interfering with autophagy by inhibition of Vacuolar protein sorting 34 (VPS34), either genetically or pharmacologically, increased CCL5 and CXCL10-medi-ated CD8 + T cell infiltration in murine melanoma and colorectal cancer [69].”
BackgroundFeng, X., Wu, B., Xu, H., Chu, C., & Ye, J. (2024) · ChemMedChem · doi:10.1002/cmdc.202400580 · Cited by 3
Regulate PD-L1's membrane orientation thermodynamics with hydrophobic nanoparticles
Lin, X., & Lin, X. (2024) · Biomaterials Science · doi:10.1039/d4bm01469c · Cited by 2
VPS34-IN1 potentiates STING-dependent activation in human CAL-1 cells
Antas, P., Machado, M. D., Leite-Pinheiro, F., Barros, D., Ramalhinho, C., Mendes, A. V., Ferreira, B. H., Carvoeiro, D. C., Mendes, L. F., Reverendo, M., et al. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00841-4 · Cited by 2
“Indeed, systemic treatment of tumor-bearing mice with VPS34 inhibitors induces a potent inflammatory signature in the tumor microenvironment, including activation of the STAT1/IRF7 pathway that is responsible for this antitumoral effect [58].”
#outubrorosa e promoção da saúde: análise das postagens no Instagram sobre o câncer de mama
Rodrigues, M. C., Garcia, L. F., & Bernuci, M. P. (2021) · Reciis · doi:10.29397/reciis.v15i4.2366 · Cited by 2
VPS34 in Autophagy, Cancer and Cancer Therapy
Bartolini, E., Janji, B., & Gao, R. (2026) · doi:10.20944/preprints202603.0323.v1 · Cited by 1
“VPS34 also regulates cellular metabolic fitness, activation, and survival in different immune cells, such as T cells, natural killer (NK) cells, and dendritic cells (DCs) [14].”
InfluentialSelf-citationLiu, Y., Zhang, H., Li, X., He, T., Zhang, W., Ji, C., & Wang, J. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10316-6 · Cited by 1
“SAR405 can also inhibit tumor progression by inducing NK cell, CD8 + T cell, and CD4 + T cell infiltration, showing significant tumor growth inhibition in melanoma and colorectal cancer when combined with anti-PD-L1/PD-1 therapy [118].”
Host PIK3C3 promotes Shigella flexneri spread from cell to cell through vacuole formation
Rolland, S., Lifschin, Z. J., Weddle, E., Yum, L. K., Miyake, T., Engel, D. A., & Agaisse, H. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1012707 · Cited by 1
“However, given the role of PIK3C3 in numerous physiological processes, the use of PIK3C3 inhibitors has been abandoned due to safety concerns [45,47,48].”
Li, S., Luo, Q., Hu, J., Duan, X., & Zhang, G. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189501 · Cited by 1
Ge, C., Wang, Z., Zhao, Z., Zhang, X., Yu, X., Chen, M., Liu, K., Lin, L., Li, D., Jin, N., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.12.020 · Cited by 1
“Although several highly specific and selective VPS34 inhibitors have been identified through screening campaigns, most have only been tested in animal models of cancer and no studies have evaluated VPS34 inhibitors for antiviral applications in vivo 21 .”
Zhang, S., Liu, M., Tan, D., Lv, K., Li, W., Huang, X., Hou, J., Yang, Y., Chen, C., Feng, J., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116769 · Cited by 2
Chen, C., Lin, J., Liang, Q., Guo, K., Li, X., Qiu, F., Kang, N., & Zhang, Q. (2026) · Molecular Carcinogenesis · doi:10.1002/mc.70081 · Cited by 1
“Surprisingly, autophagy is not limited to affecting the cancer cells themselves but also influences cancer‐associated cells, like T cells, and tumor‐associated macrophages [39, 40].”
Yin, X., Wang, L., Sun, Y., Li, S., Yu, W., Wang, S., Geng, Z., Zhao, H., & Wang, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083467 · Cited by 1
“For example, STAT1 , IRF7 and target gene CXCL10 showed up-regulated expression in the C1 group, which might impact immune function [27].”
Mishra, S. D., Mendonça, P., Kaur, S., & Soliman, K. F. A. (2026) · Cancers · doi:10.3390/cancers18091359 · Cited by 2
Targeting VPS4 elicits STING-driven anti-tumor immunity to suppress rhabdomyosarcoma growth
Zhang, R., Chen, L., Liang, X., Zhang, J., Hamamoto, K., Hattori, T., Vangala, V., Schell, T. D., Sholler, G. S., Takahashi, Y., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03800-1 · Cited by 1
Lipid Codes and Lipid‐Binding Proteins as Central Regulators of Autophagy
Kumar, A., & Ghosh, D. K. (2026) · BioFactors · doi:10.1002/biof.70124 · Cited by 1
“To overcome delivery and specificity limitations, nanoparticle-based formulations such as SAR405-loaded carriers have shown improved efficacy in preclinical studies [116, 117].”
Is targeting autophagy a promising lead to unveil the cloak of invisibility in pancreatic cancer?
Cayron, C., Rigal, S., & Guillermet‐Guibert, J. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101622 · Cited by 1
Selective VPS34 Inhibitors: High Efficiency Design by Profiting from Small Structural Differences
García-Barrantes, P. M. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01286 · Cited by 1
Chen, K., Liu, Y., Zhao, L., Shi, M., Xing, R., & Yan, X. (2024) · Research Square · doi:10.21203/rs.3.rs-5000938/v1 · Cited by 1
Autophagy repression in effector T lymphocytes redefines paradigms in T cell biology
Saxena, R., & He, Y.-W. (2025) · Nature Immunology · doi:10.1038/s41590-025-02091-0 · Cited by 1
Pan-cancer Analysis of the Prognostic and Immunological Effects of PIK3C3Preprint
Xie, Q., Zhou, J. N., Guan, J., She, S., Li, J., Liu, W., Xu, Y., Hu, M., & Tao, F. (2023) · Research Square · doi:10.21203/rs.3.rs-3268034/v1
Li, Z., Liu, K., Ye, Z., Chen, Q., Song, Y., Lu, H., Zhang, Y., Zhang, Y., Ma, X., Zan, P., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3622042/v1
Targeting transcriptional addiction in cutaneous melanoma
Cigrang, M. (2023) · theses.fr (ABES) · doi:10.70675/32a61798z3cd7z4cd8za2acza750367acaf5
Yang, L., Wei, S., Zhang, J., Hu, Q., Hu, W., Cao, M., Zhang, L., Wang, Y., Wang, P., & Wang, K. (2022) · Figshare · doi:10.6084/m9.figshare.20484978
Yang, L., Wei, S., Zhang, J., Hu, Q., Hu, W., Cao, M., Zhang, L., Wang, Y., Wang, P., & Wang, K. (2022) · Figshare · doi:10.6084/m9.figshare.20484975
Yang, L., Wei, S., Zhang, J., Hu, Q., Hu, W., Cao, M., Zhang, L., Wang, Y., Wang, P., & Wang, K. (2022) · Figshare · doi:10.6084/m9.figshare.20484987
Yang, L., Wei, S., Zhang, J., Hu, Q., Hu, W., Cao, M., Zhang, L., Wang, Y., Wang, P., & Wang, K. (2022) · Figshare · doi:10.6084/m9.figshare.20484972
Yang, L., Wei, S., Zhang, J., Hu, Q., Hu, W., Cao, M., Zhang, L., Wang, Y., Wang, P., & Wang, K. (2022) · Figshare · doi:10.6084/m9.figshare.20484984
Ye, J., Wang, H., Chakraborty, S., Sang, X., Xue, Q., Sun, M., Zhang, Y., Uher, O., Pacák, K., & Zhuang, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031340
Yang, T., Chen, J., He, Z., Li, Z., & Jiang, M. (2025) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2025.2467311
Qu, J., Wu, B., Chen, L., Wen, Z., 方梁杰, Zheng, J., Shen, Q., Heng, J., Zhou, J., & Zhou, J. (2024) · Figshare · doi:10.6084/m9.figshare.25744392
Yang, L., Wei, S., Zhang, J., Hu, Q., Hu, W., Cao, M., Zhang, L., Wang, Y., Wang, P., & Wang, K. (2022) · Figshare · doi:10.6084/m9.figshare.20484969
Tan, H., Liu, J., Huang, J., Li, Y., Xie, Q., Dong, Y., Mi, Z., Ma, X., & Rong, P. (2024) · Figshare · doi:10.6084/m9.figshare.26603755
Tan, H., Liu, J., Huang, J., Li, Y., Xie, Q., Dong, Y., Mi, Z., Ma, X., & Rong, P. (2024) · Figshare · doi:10.6084/m9.figshare.26603749
Tan, H., Liu, J., Huang, J., Li, Y., Xie, Q., Dong, Y., Mi, Z., Ma, X., & Rong, P. (2024) · Figshare · doi:10.6084/m9.figshare.26603746
Tan, H., Liu, J., Huang, J., Li, Y., Xie, Q., Dong, Y., Mi, Z., Ma, X., & Rong, P. (2024) · Figshare · doi:10.6084/m9.figshare.26603758
Zuo, Y.-H., Gao, W.-N., Xie, Y.-J., Yang, S., Zhou, J.-T., Liang, H.-H., & Fan, X.-X. (2023) · Figshare · doi:10.6084/m9.figshare.22616044
Tan, H., Liu, J., Huang, J., Li, Y., Xie, Q., Dong, Y., Mi, Z., Ma, X., & Rong, P. (2024) · Figshare · doi:10.6084/m9.figshare.26603752
Karlıtepe, A. (2023) · eArsiv - Adu (Adnan Menderes University)
The role of the MIT/TFE family in melanoma
Dias, D. B. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/s0at-ga54
Yi, Z., Li, X., Li, T., Chen, Y., Liu, W., Che, J., & Cai, H. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2025.116046
Janji, B., & Chouaïb, S. (2026) · Preprints.org · doi:10.20944/preprints202602.1320.v1
Self-citationLi, M., Song, H., Zhu, Y., Zhang, W., & Jiang, T. (2026) · Biomaterials Research · doi:10.34133/bmr.0348
“…3-kinase vacuolar protein sorting 34 (VPS34), offers dual antitumor benefits by effectively suppressing autophagic flux and reportedly enhancing antitumor immunity through increased infiltration of natural killer cells, CD4 + helper T cells, and CD8 + cytotoxic lymphocytes [ 43 , 44 ].”
Han, X., Gao, M., Quan, Y., & Zhang, C. (2026) · Nano Research · doi:10.26599/nr.2026.94908631
Toma, B., Tanasa, M. P., & Danciu, M. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189580
Impact du ciblage du domaine de liaison de HIF-1α avec HIF-1β sur le paysage immunitaire du mélanome
Lequeux, A. (2020) · theses.fr (ABES) · doi:10.70675/a29d12dbz79c1z4d37za978z2e2319131c82
Exploration of autophagy modulation in cancer and infectious diseases
Bestion, E. (2021) · theses.fr (ABES) · doi:10.70675/3663f1cdz2637z4b11za0afza7e39569a2fc
Extracellular Vesicles Enable CircRNA Delivery via in situ Biogenesis and SortingPreprint
Li, M., Pan, Y., Cui, M., Deng, J., Wang, F., Li, L., Zhang, R., Sun, C., & Li, Z. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.24.720573
Li, R., Huang, H.-Q., Yang, L.-H., Zhou, Z.-Y., & Kang, M. (2026) · BMC Cancer · doi:10.1186/s12885-026-16162-4
“IT, particularly immune checkpoint inhibitors (ICIs), has exhibited remarkable efficacy against various solid tumor types, including EC [8].”
Integrative multi-omics pipeline for analysis of checkpoint blockade therapy
Saadawy, A. H., Loay, O., & Badr, E. (2026) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-026-00821-4
“This effect also enhances the efficacy of anti-PD-L1/PD-1 immunotherapy (Chu et al. 2021, Noman et al. 2020).”
Roach, M. K., Degan, S. E., DeLiberty, J. M., Pita, L. M., Pieper, N. L., 杨闰英, Taylor, K. E., Schechter, E. G., Robb, R. N., Pierobon, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.28.734981
Zhang, Z., Gu, Y., Qiao, S., Sang, L., Zhang, L., & Zhou, F. (2026) · Cell Press Blue · doi:10.1016/j.cpblue.2026.100056 · Cited by 2
Yu, L., Dong, Q., Han, Q., Dong, S., Cheng, X., Li, J., & Ye, J. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c01571
Inhibiting PIK3C3/VPS34 enhances anti-GD2 immunotherapy in neuroblastoma
Zhang, J., Liu, X., Chen, L., Schell, T. D., Sholler, G. S., Spiegelman, V. S., Takahashi, Y., & Wang, H. (2026) · Autophagy · doi:10.1080/15548627.2026.2717948
Suri, P., Daartey, A. B., Khan, D. M. I. O., Rayana, N. P., Chilamakuri, R., Godugu, D., Azad, M. G., Reeb, K. L., & Richardson, D. R. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100158
Man Nguyen An Khanh, L. M. D., Duc, L. M., Tuan, D. T., Son, P. A., Hoang, D. H., & Ha, N. V. (2026) · Ministry of Science and Technology Vietnam · doi:10.31276/vjste.2025.0064
Vu, L., Giacobbi, N. S., Khalil, M. I., Yang, C., Eckerman, W., Recinos, E. G., Garber, J., Bennett, A. Z., Adams, B., Son, H., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-26-0421
Rational design of drug combinations for the chemoprevention of hereditary diffuse gastric cancer
Redpath, K. (2025) · Otago University Research Archive (University of Otago) · Cited by 1
BindingDB (2025) · UC San Diego · doi:10.7270/q2474gh9
BindingDB (2024) · UC San Diego · doi:10.7270/q2tm7gkb
Chu, C., Chow, N.-H., Wang, J., Chen, C., Lin, P., Yeh, Y., Lin, B., Wang, Y., Dai, Y., CHEN, Y., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.72434
“Additionally, genetic or pharmacological inhibition of PIK3C3 enhanced the efficacy of anti–PD-1/PD-L1 immunotherapy in melanoma and CRC [10].”
Metadata
- Authors
- Noman, M. Z., Parpal, S., Van Moer, K., Xiao, M., Yu, Y., Arakelian, T., Viklund, J., De Milito, A., Hasmim, M., Andersson, M., Amaravadi, R. K., Martinsson, J., Berchem, G., & Janji, B.
- Affiliations
- Luxembourg Institute of Health (LU)
- Karolinska Institutet (SE)
- Tumor Immunotherapy and Microenvironment Group, Department of Oncology, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
- Sprint Bioscience (Sweden) (SE)
- Sprint Bioscience, Stockholm, Sweden.
- Abramson Cancer Center (US)
- Centre Hospitalier de Luxembourg (LU)
- Corresponding author
- Berchem, Guy
- Janji, Bassam
- ORCID
- Venue
- Science Advances
- Published
- 2020-05
- Volume
- 6
- Issue
- 18
- Pages
- eaax7881-eaax7881
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC7190323
- OpenAlex
- W3021675475
- Cited by
- 255
- References
- 40
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 51 · 2023: 46 · 2022: 55 · 2021: 39 · 2020: 15
- FWCI
- 14.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Luxembourg National Research Fund (C18/BM/12670304/COMBATIC)
- FNRS Televie (7.4664.15; 7.6503.16; 7.4606.18)
- Fondation Cancer, Luxembourg (FC/2016/01 and FC/2018/06)
- Kriibskrank Kanner Foundation Luxembourg (2016-08-15)
- Janssen Cilag Pharma
- Action LIONS Vaincre le Cancer, Luxembourg
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- tumor immune microenvironment, PD-1/PD-L1 blockade, melanoma, colorectal cancer, T cell infiltration, RANTES, CXCL10, interferon-gamma, STAT1, IRF7, inflammatory chemokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.